Chair(s)
A/Prof. Joseph Nicolazzo, Board of Pharmaceutical Sciences and Monash University, AustraliaIntroduction
There are exciting advances in the development of biologics for a multitude of diseases given their potency and selectivity, which have significant benefits over small molecule drugs. However, inherent with biologics are issues associated with production, upscaling, stability (both intrinsic stability and long term on-shelf stability), formulation, and evaluation of pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Many of these aspects often result in poor clinical translation of biologics. This symposium will provide an overview on recent advances in the discovery, development and clinical application of various biologics, with a focus on diseases of global health.
Programme
14:30 – 14:35 | Session introduction by the chair |
14:35 – 15:15 | Deadly cures: a peptide-drug candidate for use in stroke and heart attack from venom of the Australian funnel-web spider Prof. Glenn King, The University of Queensland, Australia |
15:15 – 15:55 | Development of a heat stable oxytocin formulation for post-partum haemorrhage: Lessons learned for clinical translation Prof Michelle McIntosh, Monash University, Australia |
15:55 – 16:00 | Closing and summary |
Learning objectives
- To appreciate the current landscape on clinical translation of biologics
- To discover the current barriers to the development of novel biologics
- To appreciate current formulation strategies to assist in stabilising formulations for global health settings
Take home messages
Delegates will be exposed to the latest trends in the development of biologics for clinical implementation